ECSP088422A - Composiciones farmacéuticas sólidas que contienen pregabalina - Google Patents

Composiciones farmacéuticas sólidas que contienen pregabalina

Info

Publication number
ECSP088422A
ECSP088422A EC2008008422A ECSP088422A ECSP088422A EC SP088422 A ECSP088422 A EC SP088422A EC 2008008422 A EC2008008422 A EC 2008008422A EC SP088422 A ECSP088422 A EC SP088422A EC SP088422 A ECSP088422 A EC SP088422A
Authority
EC
Ecuador
Prior art keywords
solid pharmaceutical
pregabaline
pharmaceutical compositions
compositions containing
examples
Prior art date
Application number
EC2008008422A
Other languages
English (en)
Inventor
Zeshi Jesse Shao
Howard Norman Bockbrader
Yun Hyung Cho
Santiago Steven Diaz
Majid Mahjour
Thomas Daniel Reynold
Pushpa Ganapathi Shao
Jiansheng Wan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088422(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP088422A publication Critical patent/ECSP088422A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composición farmacéutica sólida que contiene pregabalina. La composición incluye un agente que forma una matriz y un agente de hinchamiento y es adecuada para la administración oral una vez al día. Los ejemplos de agentes que forman una matriz incluyen mezclas de poli (acetato de vinilo) y polivinilpirrolidona, y los ejemplos de agentes de hinchamiento incluyen polímeros reticulados de polivinilpirrolidona.
EC2008008422A 2005-11-02 2008-04-30 Composiciones farmacéuticas sólidas que contienen pregabalina ECSP088422A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73258905P 2005-11-02 2005-11-02

Publications (1)

Publication Number Publication Date
ECSP088422A true ECSP088422A (es) 2008-05-30

Family

ID=37965070

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008422A ECSP088422A (es) 2005-11-02 2008-04-30 Composiciones farmacéuticas sólidas que contienen pregabalina

Country Status (34)

Country Link
US (11) US20070269511A1 (es)
EP (1) EP1945186B1 (es)
JP (1) JP4334610B2 (es)
KR (1) KR101012533B1 (es)
CN (1) CN101330907B (es)
AP (1) AP2008004465A0 (es)
AR (1) AR058175A1 (es)
AU (1) AU2006310217B2 (es)
BR (1) BRPI0618211B8 (es)
CA (1) CA2628200C (es)
CR (1) CR9950A (es)
DK (1) DK1945186T3 (es)
DO (1) DOP2006000241A (es)
EA (1) EA012377B1 (es)
EC (1) ECSP088422A (es)
ES (1) ES2449231T3 (es)
GT (1) GT200600474A (es)
HK (1) HK1126394A1 (es)
IL (1) IL190827A (es)
MA (1) MA30135B1 (es)
ME (1) ME00482B (es)
NL (1) NL2000281C2 (es)
NO (1) NO20081816L (es)
NZ (1) NZ567414A (es)
PE (1) PE20070693A1 (es)
PL (1) PL1945186T3 (es)
PT (1) PT1945186E (es)
RS (1) RS20080181A (es)
SI (1) SI1945186T1 (es)
TN (1) TNSN08194A1 (es)
TW (1) TWI330080B (es)
UY (1) UY29890A1 (es)
WO (1) WO2007052125A2 (es)
ZA (1) ZA200803115B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
EP2197428B1 (en) * 2007-10-16 2012-01-25 Pharmathen S.A. Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
CL2008003800A1 (es) * 2007-12-21 2010-01-22 Synthon Bv Sal de acido sulfonico de pregabalina, procedimiento de preparacion, composicion farmaceutica, util para tratar trastornos neuropsiquiatricos, esquizofrenia, epilepsia, fibromialgia, trastorno de ansiedad generalizada, trastorno de panico y fobia social y dolor por ejemplo dolor neuropatico.
EP2307460B1 (en) * 2008-07-09 2016-11-23 Melaleuca, Inc. Mineral amino acid polysaccharide complex
CA2765172A1 (en) 2009-06-12 2010-12-16 Micro Labs Limited Novel pharmaceutical compositions containing pregabalin
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
KR101317592B1 (ko) * 2009-10-28 2013-10-15 씨제이제일제당 (주) 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
AU2011219452B2 (en) * 2010-02-24 2014-05-29 Zoetis Llc Veterinary compositions
HU230031B1 (hu) * 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
EP2555756B1 (en) * 2010-04-07 2018-08-22 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EP2389933A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Pregabalin Compositions
EP2389934A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
TR201005241A1 (tr) 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
IN2012MN02923A (es) * 2010-06-01 2015-06-05 Rubicon Res Private Ltd
EP2590636A1 (en) 2010-07-06 2013-05-15 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
EP2615913A4 (en) * 2010-09-17 2014-03-19 Panacea Biotec Ltd EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN
BR112013013525A2 (pt) 2010-12-02 2016-10-18 Ucb Pharma Gmbh formulação de liberação controlada sólida de lacosamida para administração oral, composição farmacêutica sólida, e, método para a prevenção, alívio e/ou tratamento de uma doença do sistema nervoso central
EA017542B1 (ru) * 2011-05-24 2013-01-30 Плива Кроэйша Лтд. Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
ES2586057T3 (es) * 2011-07-26 2016-10-11 Yuhan Corporation Comprimido de liberación sostenida que comprende pregabalina a través de un sistema de control de la liberación de dos fases
CN102908327B (zh) * 2011-08-05 2015-03-11 江苏恒瑞医药股份有限公司 伊伐布雷定或其可药用盐的缓释制剂
KR101438546B1 (ko) * 2011-08-26 2014-09-17 근화제약주식회사 프레가발린을 포함하는 서방성 제제
EP2809304A1 (en) 2012-01-30 2014-12-10 Ranbaxy Laboratories Limited Gastroretentive tablets
IN2014DN06965A (es) 2012-01-30 2015-04-10 Ranbaxy Lab Ltd
CN102743357A (zh) * 2012-06-26 2012-10-24 严轶东 一种普瑞巴林胃内泡腾漂浮缓释制剂及其制备方法
US9861585B2 (en) 2012-10-16 2018-01-09 Sun Pharmaceutical Industries Limited Osmotic floating tablets
WO2015114655A2 (en) * 2014-01-21 2015-08-06 Intas Pharmaceuticals Limited Modified release tablet of pregabalin
EP3099288A1 (en) 2014-01-28 2016-12-07 Sun Pharmaceutical Industries Ltd Stabilized gastroretentive tablets of pregabalin
KR102221846B1 (ko) * 2014-04-07 2021-02-26 영진약품 주식회사 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
CN111840239B (zh) * 2014-10-24 2022-11-18 江苏恒瑞医药股份有限公司 一种普瑞巴林缓释制剂
CN104906064B (zh) * 2015-05-15 2017-12-22 中国药科大学 一种普瑞巴林胃漂浮缓释片剂及其制备方法
US9747110B2 (en) * 2015-05-20 2017-08-29 Altera Corporation Pipelined cascaded digital signal processing structures and methods
JP2018520112A (ja) * 2015-05-26 2018-07-26 オディディ，イサ 制御持続放出プレガバリン
CN104840443B (zh) * 2015-05-27 2018-04-27 齐鲁制药有限公司 含活性成分普瑞巴林的药物组合物
EP3484456A4 (en) 2016-07-17 2020-03-18 Mapi Pharma Limited RETARD PHARMACEUTICAL FORMS OF PREGABALIN
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP2019142834A (ja) * 2017-07-31 2019-08-29 大原薬品工業株式会社 プレガバリン並びに好適な賦形剤を含有する固形製剤
WO2019146642A1 (ja) * 2018-01-24 2019-08-01 大原薬品工業株式会社 γ－アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法
CN110585153A (zh) * 2018-06-13 2019-12-20 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
US11938222B2 (en) 2018-06-13 2024-03-26 Beijing Tide Pharmaceutical Co., Ltd. Pregabalin sustained release composition and method for preparing the same
CN111053749B (zh) * 2018-10-16 2022-07-15 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CA3105212A1 (en) * 2018-06-28 2020-01-02 Mylan Inc. Pregabalin extended-release formulations
CN109044981B (zh) * 2018-08-07 2021-02-19 广州帝奇医药技术有限公司 一种普瑞巴林胃漂浮型缓释片及其制备方法
DK3760190T3 (da) 2019-07-03 2023-09-04 Alvogen Inc Tabletter af pregabalin med forlænget frigivelse, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
CN110974798A (zh) * 2019-12-19 2020-04-10 江苏优仿医药科技有限公司 药物组合物、缓释片剂及其制备方法
TW202300138A (zh) * 2021-03-17 2023-01-01 大陸商上海博志研新藥物技術有限公司 拉考沙胺藥物組合物、其製備方法及應用
CN113577036B (zh) * 2021-05-31 2023-04-04 石药集团欧意药业有限公司 一种普瑞巴林胃漂浮缓释片及其制备方法
GB2624861A (en) * 2022-11-28 2024-06-05 Orbit Pharma Ltd Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483751D1 (de) 1983-05-02 1991-01-31 Diamond Scient Co Photochemische entkeimungsbehandlung von vollem blut oder blutbestandteilen.
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5616793A (en) * 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6271278B1 (en) 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
US6120803A (en) 1997-08-11 2000-09-19 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
IN186245B (es) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
HU228771B1 (en) 1998-05-15 2013-05-28 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
AU769038B2 (en) 1998-05-15 2004-01-15 Warner-Lambert Company Llc Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
AU777046B2 (en) * 2000-01-27 2004-09-30 Warner-Lambert Company Llc Asymmetric synthesis of pregabalin
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US6531509B2 (en) 2000-06-16 2003-03-11 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
CZ2003199A3 (cs) 2000-06-23 2003-12-17 Teva Pharmaceutical Industries Ltd. Rychle expandující kompozice pro řízené uvolňování léčiva a retenci léčiva v žaludku a lékové formy obsahující tuto kompozici
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
EP1670451A4 (en) * 2003-09-11 2009-10-21 Xenoport Inc TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
JP2007509974A (ja) 2003-10-31 2007-04-19 アルザ・コーポレーシヨン ３−アミノプロピル−ｎ−ブチルホスフィン酸の増大した吸収のための組成物および薬用量形態

Also Published As

Publication number Publication date
US8945620B2 (en) 2015-02-03
PT1945186E (pt) 2014-03-06
AU2006310217A1 (en) 2007-05-10
AR058175A1 (es) 2008-01-23
UY29890A1 (es) 2007-05-31
DK1945186T3 (en) 2014-03-17
TNSN08194A1 (fr) 2009-10-30
SI1945186T1 (sl) 2014-03-31
US20130102675A1 (en) 2013-04-25
CN101330907B (zh) 2012-08-29
EA012377B1 (ru) 2009-10-30
NZ567414A (en) 2011-09-30
MA30135B1 (fr) 2009-01-02
ZA200803115B (en) 2009-09-30
US20150094371A1 (en) 2015-04-02
US20120232149A1 (en) 2012-09-13
ME00482B (me) 2011-10-10
US20160250147A1 (en) 2016-09-01
NO20081816L (no) 2008-05-08
AU2006310217B2 (en) 2012-08-16
BRPI0618211B8 (pt) 2021-05-25
WO2007052125A2 (en) 2007-05-10
CN101330907A (zh) 2008-12-24
US20170348420A1 (en) 2017-12-07
BRPI0618211A2 (pt) 2011-08-23
CA2628200A1 (en) 2007-05-10
US9144559B2 (en) 2015-09-29
KR101012533B1 (ko) 2011-02-07
JP2009514847A (ja) 2009-04-09
HK1126394A1 (en) 2009-09-04
US10022447B2 (en) 2018-07-17
KR20080059427A (ko) 2008-06-27
WO2007052125A3 (en) 2007-09-07
TWI330080B (en) 2010-09-11
RS20080181A (en) 2009-07-15
ES2449231T3 (es) 2014-03-18
BRPI0618211B1 (pt) 2020-11-17
EP1945186B1 (en) 2014-01-22
IL190827A (en) 2012-08-30
CA2628200C (en) 2011-01-25
IL190827A0 (en) 2008-12-29
PL1945186T3 (pl) 2014-05-30
EP1945186A2 (en) 2008-07-23
AP2008004465A0 (en) 2008-06-30
PE20070693A1 (es) 2007-08-11
US20120029081A1 (en) 2012-02-02
GT200600474A (es) 2007-06-08
JP4334610B2 (ja) 2009-09-30
US20130303618A1 (en) 2013-11-14
US20170136125A1 (en) 2017-05-18
US20150352066A1 (en) 2015-12-10
DOP2006000241A (es) 2007-05-31
EA200800931A1 (ru) 2008-10-30
NL2000281A1 (nl) 2007-05-03
US20070269511A1 (en) 2007-11-22
CR9950A (es) 2008-05-28
TW200803831A (en) 2008-01-16
NL2000281C2 (nl) 2007-08-07
US20140163103A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
ECSP088422A (es) Composiciones farmacéuticas sólidas que contienen pregabalina
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
CR7500A (es) Formas de dosificacion de azitromicida con efectos secundarios reducidos
CL2004000416A1 (es) Compuestos heterociclicos nitrogenados; composicion farmaceutica; y uso del compuesto para tratar o prevenir una condicion mediada por p38, que consiste en una enfermedad inflamatoria, autoinmune, virosica o neurodegenerativa.
AR054238A1 (es) Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
GT200600307A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
AR057474A1 (es) Composiciones de donepezil gelificado y metodos para la fabricacion y utilizacion de las mismas
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
UY27727A1 (es) Nueva composicion farmacéutica-
UY28457A1 (es) Nueva composición
PE20070464A1 (es) Forma farmaceutica con liberacion sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
SV2006002224A (es) Composicion farmaceutica ref. bhco41368-sv
AR067351A1 (es) Combinacion de picotamida con nafronil
CR8973A (es) Composicion farmaceutica en forma de una forma de dosificacion solida soluble en agua
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
AR046043A1 (es) Asociacion de un agente anti-aterotrombotico y un agente anti-agregacion de plaquetas y composiciones farmaceuticas que los contienen
PT1499278E (pt) Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa
JP2004224775A5 (es)